Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02383849
Recruitment Status : Enrolling by invitation
First Posted : March 9, 2015
Last Update Posted : February 8, 2019
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Brief Summary:
P1106 is Phase IV prospective pharmacokinetic (PK) study of low birth weight infants who are receiving or will be receiving as part of clinical care nevirapine (NVP) prophylaxis, tuberculosis (TB) prophylaxis or treatment and/or combination antiretroviral (ARV) treatment containing lopinavir/ritonavir (LPV/r). The study is designed to describe the pharmacokinetics and safety of NVP, INH, RIF, and LPV/r in these infants receiving the drug(s) as part of clinical care.

Condition or disease
Low-Birth-Weight Infant Tuberculosis HIV

Layout table for study information
Study Type : Observational
Estimated Enrollment : 158 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants
Study Start Date : July 2015
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine


Group/Cohort
Arm 1
Breastfeeding infants 7 to 14 days of age with birth weight less than or equal to 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected and TB negative; infant receiving NVP prophylaxis but not TB prophylaxis or treatment
Arm 2
Breastfeeding infants 7 to 14 days of age with birth weight less than or equal to 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus isoniazid (INH) but not rifampicin (RIF) for TB prophylaxis
Arm 3
Breastfeeding infants 7 to 14 days of age with birth weight less than or equal to 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus INH plus RIF for TB prophylaxis or treatment
Arm 4
Breast or formula feeding infants 7 to 14 days of age with birth weight less than or equal to 2500 grams born to HIV-uninfected mothers with active TB disease; infant receiving INH alone or INH plus RIF for TB prophylaxis
Arm 5
Breast or formula feeding infants newly diagnosed with HIV infection weighing less than or equal to 2500 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 5 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and not receiving RIF (but may be receiving INH)
Arm 6
Breast or formula feeding infants newly diagnosed with HIV infection weighing less than or equal to 2500 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 6 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and receiving RIF (and may be receiving INH)



Primary Outcome Measures :
  1. Apparent clearance (CL/F) of NVP, INH, RIF, and LPV/r [ Time Frame: Week 24 of life ]

Secondary Outcome Measures :
  1. Primary safety endpoints [ Time Frame: Study duration ]
    Number of participants with adverse events of grade 3 or 4 severity, death, or serious adverse clinical events


Biospecimen Retention:   Samples With DNA
Cell pellets from PK sampling once will be combined and stored for a DNA extraction, amplification, and gel electrophoresis. The genotype analysis will be completed one time per study participant. All subjects receiving INH will be genotyped for NAT2. All subjects receiving NVP will be genotyped for CYP 2B6. These genotypes will be used as covariates in the population PK analyses of NVP and INH to determine their impact on CL/F (clearance [apparent]).


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 84 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Low birth weight (LBW) infants less than or equal to 2500 grams at birth who are receiving or will be receiving as part of clinical care nevirapine (NVP) prophylaxis, tuberculosis (TB) prophylaxis or treatment and/or combination antiretroviral (ARV) treatment containing lopinavir/ritonavir (LPV/r)
Criteria

Inclusion Criteria:

Inclusion Criteria for Arms 1, 2 and 3 (HIV-exposed infants):

  • Breastfeeding infants born to HIV-infected mothers who are receiving either no ARV therapy or ARV therapy that does not include NVP
  • Age 7 to 14 days
  • Birth weight less than or equal to 2500 grams
  • Receiving or will be receiving prophylaxis as prescribed by clinical care provider as follows: NVP (Arm 1), NVP plus INH (Arm 2), NVP plus INH plus RIF (Arm 3)
  • Parent or legal guardian able and willing to provide written informed consent. [Note to sites: modify per locally relevant language].

Inclusion Criteria for Arm 4 (HIV-unexposed but TB exposed infants):

  • Age 7 to 14 days
  • Birth weight less than or equal to 2500 grams
  • Receiving prophylaxis with INH alone or INH plus RIF as prescribed by clinical care provider
  • Not receiving any therapy for HIV prophylaxis or treatment
  • Parent or legal guardian able and willing to provide written informed consent. [Note to sites: modify per locally relevant language].

Inclusion Criteria for Arms 5 and 6 (HIV-infected infants):

  • Documentation of HIV-1 infection defined as positive HIV DNA PCR done as part of clinical care. An HIV RNA confirmatory test must be done at study entry but results may be pending at time of enrollment.
  • Birth weight less than or equal to 2500 grams
  • Age less than or equal to 12 weeks (defined as 84 days)
  • Intention by clinical care provider to prescribe LPV/r plus 2 NRTIs and no RIF (Arm 5) or LPV/r plus 2 NRTIs plus RIF (Arm 6)
  • Parent or legally acceptable representative able and willing to provide written informed consent. [Note to sites: modify per locally relevant language].

Exclusion Criteria:

Any severe congenital malformation or other medical condition incompatible with life or that would interfere with study participation or interpretation, as judged by the examining clinician.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02383849


Locations
Layout table for location information
South Africa
Soweto IMPAACT CRS (8052)
Johannesburg, Gauteng, South Africa, 1862
Family Clinical Research Unit (FAM-CRU) CRS (8950)
Tygerberg, Western Cape Province, South Africa, 7505
Sponsors and Collaborators
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Investigators
Layout table for investigator information
Study Chair: Mark Cotton, MD, MBChB, FCPaed, MMED University of Stellenbosch
Study Chair: Mark H Mirochnick, MD Boston Medical Center

Layout table for additonal information
Responsible Party: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
ClinicalTrials.gov Identifier: NCT02383849     History of Changes
Other Study ID Numbers: IMPAACT P1106
11882 ( Other Identifier: DAIDS )
First Posted: March 9, 2015    Key Record Dates
Last Update Posted: February 8, 2019
Last Verified: February 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Body Weight
Tuberculosis
Birth Weight
Signs and Symptoms
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents